Checkpoint Cash Ratio from 2010 to 2025

CKPT Stock  USD 2.86  0.15  5.54%   
Checkpoint Therapeutics Cash Ratio yearly trend continues to be comparatively stable with very little volatility. Cash Ratio will likely drop to 0.29 in 2025. From the period from 2010 to 2025, Checkpoint Therapeutics Cash Ratio quarterly data regression had r-value of (0.89) and coefficient of variation of  106.16. View All Fundamentals
 
Cash Ratio  
First Reported
2010-12-31
Previous Quarter
0.31
Current Value
0.29
Quarterly Volatility
12.96853508
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Checkpoint Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Checkpoint Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 102.1 K, Depreciation And Amortization of 183.4 K or Interest Expense of 5.2 M, as well as many indicators such as Price To Sales Ratio of 394, Dividend Yield of 0.0 or Days Sales Outstanding of 168. Checkpoint financial statements analysis is a perfect complement when working with Checkpoint Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Checkpoint Therapeutics Correlation against competitors.
For more information on how to buy Checkpoint Stock please use our How to Invest in Checkpoint Therapeutics guide.

Latest Checkpoint Therapeutics' Cash Ratio Growth Pattern

Below is the plot of the Cash Ratio of Checkpoint Therapeutics over the last few years. It is Checkpoint Therapeutics' Cash Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Checkpoint Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Cash Ratio10 Years Trend
Slightly volatile
   Cash Ratio   
       Timeline  

Checkpoint Cash Ratio Regression Statistics

Arithmetic Mean12.22
Geometric Mean4.16
Coefficient Of Variation106.16
Mean Deviation11.96
Median5.65
Standard Deviation12.97
Sample Variance168.18
Range27.899
R-Value(0.89)
Mean Square Error36.74
R-Squared0.80
Slope(2.43)
Total Sum of Squares2,523

Checkpoint Cash Ratio History

2025 0.29
2024 0.31
2023 0.27
2022 0.37
2021 2.11
2020 5.65
2019 3.21

About Checkpoint Therapeutics Financial Statements

Checkpoint Therapeutics shareholders use historical fundamental indicators, such as Cash Ratio, to determine how well the company is positioned to perform in the future. Although Checkpoint Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Checkpoint Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Checkpoint Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cash Ratio 0.31  0.29 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Checkpoint Stock Analysis

When running Checkpoint Therapeutics' price analysis, check to measure Checkpoint Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Checkpoint Therapeutics is operating at the current time. Most of Checkpoint Therapeutics' value examination focuses on studying past and present price action to predict the probability of Checkpoint Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Checkpoint Therapeutics' price. Additionally, you may evaluate how the addition of Checkpoint Therapeutics to your portfolios can decrease your overall portfolio volatility.